Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Asakura M, Kim J, Asanuma H, Hamasaki T, Tsukahara K, Higashino Y, Ishikawa T, Nakama Y, Koba S, Maruyama Y, Tsujimoto M, Himeno H, Ohkusa T, Fujino S, Shimizu M, Endo T, Yoda S, Muroya T, Murohara T, Ohte N, Suzuki H, Kohno T, Fukui K, Shiono T, Takase H, Uzui H, Nagai Y, Hashimoto Y, Ikeda S, Mizuno S, Tamita K, Fujita M, Satake K, Kinoshita Y, Nunohiro T, Sakagami S, Higaki J, Morii I, Sawada R, Hiasa Y, Shigemasa T, Nakahama M, Sata M, Doi O, Ueda T, Yamada T, Yamanouchi T, Yamaguchi H, Morita Y, Hayashi H, Kitakaze M; ABC investigators. Asakura M, et al. Among authors: tsujimoto m. Cardiovasc Drugs Ther. 2017 Aug;31(4):401-411. doi: 10.1007/s10557-017-6740-3. Cardiovasc Drugs Ther. 2017. PMID: 28779371 Clinical Trial.
Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone: Reports of a Randomised Trial From The Japan Working Group for the Assessment Whether Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study).
Asakura M, Kim J, Asanuma H, Nakama Y, Tsukahara K, Higashino Y, Ishikawa T, Koba S, Tsujimoto M, Himeno H, Maruyama Y, Ookusa T, Yoda S, Suzuki H, Okubo S, Shimizu M, Hashimoto Y, Satake K, Fujino S, Uzui H, Nagai Y, Kohno T, Mizuno S, Nakahama M, Kanaya H, Murohara T, Fukui K, Takase H, Ohte N, Shiono T, Fukunami M, Endo T, Sawada R, Fujii K, Takeuchi M, Ikeda S, Mizuno K, Uematsu M, Matsubara T, Yano S, Takahashi J, Ueda K, Kinoshita Y, Tamita K, Hayashi H, Hamasaki T, Kitakaze M; PPAR investigators. Asakura M, et al. Among authors: tsujimoto m. EClinicalMedicine. 2018 Oct 22;4-5:10-24. doi: 10.1016/j.eclinm.2018.09.006. eCollection 2018 Oct-Nov. EClinicalMedicine. 2018. PMID: 31193597 Free PMC article.
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial.
Asakura M, Ito S, Yamada T, Saito Y, Kimura K, Yamashina A, Hirayama A, Kobayashi Y, Hanatani A, Tsujimoto M, Yasuda S, Abe Y, Higashino Y, Tamaki Y, Sugino H, Niinuma H, Okuhara Y, Koitabashi T, Momomura SI, Asai K, Nomura A, Kawai H, Satoh Y, Yoshikawa T, Hirata KI, Yokoi Y, Tanaka J, Shibata Y, Maejima Y, Tamaki S, Kawata H, Iwahashi N, Kobayashi M, Higuchi Y, Kada A, Yamamoto H, Kitakaze M. Asakura M, et al. Among authors: tsujimoto m. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):108-117. doi: 10.1093/ehjcvp/pvaa132. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 33175088 Clinical Trial.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Teerlink JR, et al. N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33185990 Free article. Clinical Trial.
Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
Ueda H, Kido A, Matsuhisa S, Asawa K, Yoshida N, Tsujimoto M, Sasaki Y, Kuga Y, Yamasaki M, Ueda K, Shinohara S, Nishida Y. Ueda H, et al. Among authors: tsujimoto m. Am Heart J. 2016 Mar;173:134-42. doi: 10.1016/j.ahj.2015.12.014. Epub 2015 Dec 31. Am Heart J. 2016. PMID: 26920606 Clinical Trial.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RI; CREDENCE Trial Investigators*. Zhou Z, et al. Stroke. 2021 May;52(5):1545-1556. doi: 10.1161/STROKEAHA.120.031623. Epub 2021 Apr 20. Stroke. 2021. PMID: 33874750 Free PMC article. Clinical Trial.
819 results